<DOC>
	<DOC>NCT00933348</DOC>
	<brief_summary>The purpose of this study is to examine the safety and efficacy of the fruit-based product OPAL A for the treatment of chronic venous and pressure ulcers.</brief_summary>
	<brief_title>Safety and Efficacy of the Fruit-based Product OPAL A for the Treatment of Chronic Venous and Pressure Ulcers</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Pressure Ulcer</mesh_term>
	<mesh_term>Varicose Ulcer</mesh_term>
	<criteria>Male or female. Aged ≥ 18 years. Presence of either: a venous leg ulcer with a surface area ≥ 2 cm2 and &lt; 25 cm2 (best estimate of debrided wound), OR a Stage II or III pressure ulcer (as per Australian Wound Management Association [AWMA] definitions) Able to tolerate compression therapy (for venous ulcer group only) Willing and able to provide written informed consent Additional inclusion criterion after fourweek standard care runin period: a less than or equal to 25% reduction in wound surface area compared with wound surface area at the screening visit Another ulcer within 10 cm of the ulcer to be treated Patients with diabetes (fasting blood glucose value ≥ 7 mmol/L or random blood glucose &gt; 11 mmol/L) that in the opinion of the investigator is uncontrolled Anklebrachial pressure index of &lt; 0.8 (participants with venous ulcers only) Alanine transaminase (ALT) or aspartate transaminase (AST) levels 3X the upper limit of normal Any dermatologic condition or disorder (with the exception of dermatitis associated with venous stasis) that may interfere with the appropriate assessment and treatment of the participant's ulcer Clinical signs of ulcer infection. Current or recent (within the past two weeks) daily treatment with immunosuppressive medications (including oral corticosteroids; inhaled and topical corticosteroids are permitted; topical agents must not be applied within 10 cm of ulcer wound), cytotoxins or antiinflammatory agents (intermittent nonsteroidal antiinflammatory agent use is permitted) Known hypersensitivity to paw paw products Pregnancy, planned pregnancy or lactation Participation in another clinical trial within one month of study entry Another disease or condition that in the opinion of the investigator may jeopardize the safety of the participant or their ability to participate in the study Participant previously screened or randomized in this study Cognitive impairment that in the opinion of the investigator leaves the participant incapable of providing informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>ulcer</keyword>
	<keyword>venous</keyword>
	<keyword>pressure</keyword>
	<keyword>wound</keyword>
	<keyword>treatment</keyword>
</DOC>